Brief: Tracon Pharmaceuticals Announces Results From Review Of Interim Safety And Efficacy Data From Envasarc Pivotal Trial
27/12/2021 13:24
Dec 27 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM THE
INDEPENDENT DATA MONITORING COMMITTEE REVIEW OF INTERIM SAFETY
AND EFFICACY DATA FROM THE ONGOING ENVASARC PIVOTAL TRIAL
* TRACON PHARMACEUTICALS - ENVAFOLIMAB WELL TOLERATED AS A
SINGLE
AGENT AND IN COMBINATION WITH YERVOY
Source text for Eikon: ID:nGNXc1MK6X
Further company coverage: TCON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants